Interactions with atorvastatin
Searched over 200M research papers
Summary
10 papers analyzed
Some studies suggest atorvastatin has no significant interaction with fenofibrate, while other studies indicate it interacts with cyclosporine A, dronedarone, omega-3 fatty acids, and boosted antiretrovirals, potentially affecting its pharmacokinetics and efficacy.
Not a yes or no question
To use the Consensus Meter, try asking a simple yes or no question
Research summarized with Copilot
Beta20 papers analyzed
Interactions with Atorvastatin: A Comprehensive Overview
Atorvastatin and Fenofibrate: No Significant Pharmacokinetic Interaction
A study investigating the pharmacokinetic interaction between atorvastatin (ATO) and fenofibrate (FNO) found no significant clinical-pharmacokinetic interaction between the two drugs. The study involved healthy volunteers who were administered ATO alone and in combination with FNO. The results showed that the area under the concentration-time curve (AUC) and maximum plasma drug concentration (Cmax) for the combination were within acceptable bioequivalence limits compared to ATO alone, suggesting no relevant interaction.
Atorvastatin and Cyclosporin A: Increased Cyclosporin Levels
In renal transplant recipients treated with cyclosporin A (CsA), atorvastatin was found to increase CsA blood trough levels in some patients. Specifically, four out of ten patients experienced a rise in CsA levels by more than 25% within 7-14 days of starting atorvastatin therapy. This interaction necessitates careful monitoring of CsA levels when co-administered with atorvastatin .
Atorvastatin and Dronedarone: Modulation by CYP3A4
Atorvastatin and its lactone form (ARVL) interact with dronedarone (DND) through the enzyme CYP3A4. Both ARVL and ARVS inhibit DND binding and metabolism, with ARVL showing a higher affinity for CYP3A4. This interaction highlights the importance of considering the metabolic pathways involved when co-administering these drugs.
Atorvastatin and Omega-3 Fatty Acids: Pharmacokinetic Interaction
A phase 1 trial evaluated the interaction between atorvastatin and omega-3 fatty acids. The study found that co-administration altered the pharmacokinetics of both atorvastatin and its metabolite, 2-OH-atorvastatin, as well as the omega-3 fatty acids DHA and EPA. The results indicated a significant pharmacokinetic interaction, suggesting that dose adjustments may be necessary when these agents are used together.
Atorvastatin and Antiretrovirals: Variable Effects
In people living with HIV, atorvastatin's pharmacokinetics are significantly influenced by co-administration with antiretrovirals (ARVs). Boosted ARVs were found to decrease atorvastatin clearance and slow down the formation of its major metabolite, leading to increased atorvastatin exposure. Conversely, CYP3A4 inducers increased atorvastatin clearance. These findings underscore the need for individualized dosing strategies in this population.
Atorvastatin and Bile Acids: Impaired Insulinotropic Effects
Atorvastatin interacts with the farnesoid X receptor (FXR), impairing the insulinotropic effects of bile acids like chenodeoxycholic acid (CDC). This interaction may contribute to the diabetogenic risk associated with statin therapy, as atorvastatin inhibits insulin release and negates the positive effects of bile acids on beta cell function.
Conclusion
Atorvastatin, a widely used statin, exhibits various drug-drug interactions that can significantly impact its pharmacokinetics and therapeutic efficacy. These interactions necessitate careful consideration and monitoring, particularly when atorvastatin is co-administered with drugs like cyclosporin A, dronedarone, omega-3 fatty acids, and antiretrovirals. Understanding these interactions is crucial for optimizing treatment regimens and ensuring patient safety.
Sources and full results
Most relevant research papers on this topic
